AU2038683A - Bicyclic heteroaryl substituted pyridone compounds - Google Patents
Bicyclic heteroaryl substituted pyridone compoundsInfo
- Publication number
- AU2038683A AU2038683A AU20386/83A AU2038683A AU2038683A AU 2038683 A AU2038683 A AU 2038683A AU 20386/83 A AU20386/83 A AU 20386/83A AU 2038683 A AU2038683 A AU 2038683A AU 2038683 A AU2038683 A AU 2038683A
- Authority
- AU
- Australia
- Prior art keywords
- quinolinyl
- hydrogen
- halo
- compound according
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical class OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 title description 6
- 150000001875 compounds Chemical class 0.000 claims description 49
- -1 cyano, amino, guanidino, thioureido, ureido, carboxyl Chemical group 0.000 claims description 43
- 229910052739 hydrogen Inorganic materials 0.000 claims description 35
- 239000001257 hydrogen Substances 0.000 claims description 35
- 150000003839 salts Chemical class 0.000 claims description 31
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 27
- 125000000217 alkyl group Chemical group 0.000 claims description 26
- 239000000203 mixture Substances 0.000 claims description 14
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 13
- 239000002253 acid Substances 0.000 claims description 12
- 125000003545 alkoxy group Chemical group 0.000 claims description 12
- 125000003282 alkyl amino group Chemical group 0.000 claims description 12
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
- 125000004442 acylamino group Chemical group 0.000 claims description 10
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 10
- 125000001072 heteroaryl group Chemical group 0.000 claims description 10
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 9
- 125000001188 haloalkyl group Chemical group 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 230000003177 cardiotonic effect Effects 0.000 claims description 8
- 231100000252 nontoxic Toxicity 0.000 claims description 8
- 230000003000 nontoxic effect Effects 0.000 claims description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 7
- 125000002619 bicyclic group Chemical group 0.000 claims description 6
- 230000000747 cardiac effect Effects 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 5
- QOKCNBKUVXSSIA-UHFFFAOYSA-N 2-oxo-5-quinolin-4-yl-1h-pyridine-3-carboxamide Chemical compound N1C(=O)C(C(=O)N)=CC(C=2C3=CC=CC=C3N=CC=2)=C1 QOKCNBKUVXSSIA-UHFFFAOYSA-N 0.000 claims description 4
- KMLASFJDBOFNIC-UHFFFAOYSA-N 3-bromo-5-quinolin-4-yl-1h-pyridin-2-one Chemical compound N1C(=O)C(Br)=CC(C=2C3=CC=CC=C3N=CC=2)=C1 KMLASFJDBOFNIC-UHFFFAOYSA-N 0.000 claims description 4
- WGLOMJFPOLSSRT-UHFFFAOYSA-N 5-quinolin-4-yl-1h-pyridin-2-one Chemical compound N1C(=O)C=CC(C=2C3=CC=CC=C3N=CC=2)=C1 WGLOMJFPOLSSRT-UHFFFAOYSA-N 0.000 claims description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 125000002030 1,2-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([*:2])C([H])=C1[H] 0.000 claims description 2
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims description 2
- JALWWPXKYDRONG-UHFFFAOYSA-N 2-oxo-5-quinolin-4-yl-1h-pyridine-3-carboxylic acid Chemical compound N1C(=O)C(C(=O)O)=CC(C=2C3=CC=CC=C3N=CC=2)=C1 JALWWPXKYDRONG-UHFFFAOYSA-N 0.000 claims description 2
- ZHKOAJMXNNSMES-UHFFFAOYSA-N 3-bromo-1-ethyl-5-quinolin-4-ylpyridin-2-one Chemical compound C1=C(Br)C(=O)N(CC)C=C1C1=CC=NC2=CC=CC=C12 ZHKOAJMXNNSMES-UHFFFAOYSA-N 0.000 claims description 2
- LJWCFBGEFVVEJK-UHFFFAOYSA-N 3-bromo-1-methyl-5-quinolin-4-ylpyridin-2-one Chemical compound C1=C(Br)C(=O)N(C)C=C1C1=CC=NC2=CC=CC=C12 LJWCFBGEFVVEJK-UHFFFAOYSA-N 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims 10
- SZPWXAOBLNYOHY-UHFFFAOYSA-N [C]1=CC=NC2=CC=CC=C12 Chemical group [C]1=CC=NC2=CC=CC=C12 SZPWXAOBLNYOHY-UHFFFAOYSA-N 0.000 claims 5
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Chemical group C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 claims 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical group C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 claims 1
- 239000007787 solid Substances 0.000 description 25
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 20
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 239000011541 reaction mixture Substances 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 125000005843 halogen group Chemical group 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 206010019280 Heart failures Diseases 0.000 description 7
- 125000004432 carbon atom Chemical group C* 0.000 description 7
- 239000012458 free base Substances 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000000297 inotrophic effect Effects 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- 206010007559 Cardiac failure congestive Diseases 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- 239000000496 cardiotonic agent Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000012467 final product Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 4
- 238000001291 vacuum drying Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- RNLQIBCLLYYYFJ-UHFFFAOYSA-N amrinone Chemical compound N1C(=O)C(N)=CC(C=2C=CN=CC=2)=C1 RNLQIBCLLYYYFJ-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical group O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 description 3
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- 230000002107 myocardial effect Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000009090 positive inotropic effect Effects 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- MUDSDYNRBDKLGK-UHFFFAOYSA-N 4-methylquinoline Chemical compound C1=CC=C2C(C)=CC=NC2=C1 MUDSDYNRBDKLGK-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- 208000020446 Cardiac disease Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 229960002105 amrinone Drugs 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 2
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 210000002837 heart atrium Anatomy 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 150000007975 iminium salts Chemical class 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- AAWZDTNXLSGCEK-LNVDRNJUSA-N (3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid Chemical compound O[C@@H]1CC(O)(C(O)=O)C[C@@H](O)C1O AAWZDTNXLSGCEK-LNVDRNJUSA-N 0.000 description 1
- DJDDYWYYTKNZPM-UHFFFAOYSA-N 2-amino-1,3-dioxane-4,6-dione Chemical compound NC1OC(=O)CC(=O)O1 DJDDYWYYTKNZPM-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- DYUMBFTYRJMAFK-UHFFFAOYSA-N 3-cyano-2-pyridone Chemical compound OC1=NC=CC=C1C#N DYUMBFTYRJMAFK-UHFFFAOYSA-N 0.000 description 1
- KWFQLEGOEWMCCK-UHFFFAOYSA-N 3-ethyl-1h-pyridin-2-one Chemical compound CCC1=CC=CNC1=O KWFQLEGOEWMCCK-UHFFFAOYSA-N 0.000 description 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
- MVKDNXIKAWKCCS-UHFFFAOYSA-N 3-methyl-1h-pyridin-2-one Chemical compound CC1=CC=CN=C1O MVKDNXIKAWKCCS-UHFFFAOYSA-N 0.000 description 1
- NHWKTZWOSIVHOL-UHFFFAOYSA-N 5-pyridin-2-yl-1h-pyridin-2-one Chemical compound N1C(=O)C=CC(C=2N=CC=CC=2)=C1 NHWKTZWOSIVHOL-UHFFFAOYSA-N 0.000 description 1
- JLEJXZDPNYUTIR-UHFFFAOYSA-N 5-pyridin-4-yl-1h-pyridin-2-one Chemical class N1C(=O)C=CC(C=2C=CN=CC=2)=C1 JLEJXZDPNYUTIR-UHFFFAOYSA-N 0.000 description 1
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- AAWZDTNXLSGCEK-UHFFFAOYSA-N Cordycepinsaeure Natural products OC1CC(O)(C(O)=O)CC(O)C1O AAWZDTNXLSGCEK-UHFFFAOYSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 240000001879 Digitalis lutea Species 0.000 description 1
- JRWZLRBJNMZMFE-UHFFFAOYSA-N Dobutamine Chemical compound C=1C=C(O)C(O)=CC=1CCNC(C)CCC1=CC=C(O)C=C1 JRWZLRBJNMZMFE-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- AAWZDTNXLSGCEK-ZHQZDSKASA-N Quinic acid Natural products O[C@H]1CC(O)(C(O)=O)C[C@H](O)C1O AAWZDTNXLSGCEK-ZHQZDSKASA-N 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 150000001728 carbonyl compounds Chemical class 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- QQVDYSUDFZZPSU-UHFFFAOYSA-M chloromethylidene(dimethyl)azanium;chloride Chemical compound [Cl-].C[N+](C)=CCl QQVDYSUDFZZPSU-UHFFFAOYSA-M 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- DGJMPUGMZIKDRO-UHFFFAOYSA-N cyanoacetamide Chemical compound NC(=O)CC#N DGJMPUGMZIKDRO-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000002478 diastatic effect Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229960001089 dobutamine Drugs 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000004041 inotropic agent Substances 0.000 description 1
- 229940124975 inotropic drug Drugs 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- WRIRWRKPLXCTFD-UHFFFAOYSA-N malonamide Chemical compound NC(=O)CC(N)=O WRIRWRKPLXCTFD-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- AGJSNMGHAVDLRQ-IWFBPKFRSA-N methyl (2s)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-amino-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxy-2,3-dimethylphenyl)propanoyl]amino]-4-methylsulfanylbutanoate Chemical compound SC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCSC)C(=O)OC)CC1=CC=C(O)C(C)=C1C AGJSNMGHAVDLRQ-IWFBPKFRSA-N 0.000 description 1
- VEJIXXYMFIXNAS-UHFFFAOYSA-N methyl(methylidene)azanium chloride hydrochloride Chemical compound Cl.[Cl-].C[NH+]=C VEJIXXYMFIXNAS-UHFFFAOYSA-N 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- ZHNFLHYOFXQIOW-LPYZJUEESA-N quinine sulfate dihydrate Chemical compound [H+].[H+].O.O.[O-]S([O-])(=O)=O.C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21.C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 ZHNFLHYOFXQIOW-LPYZJUEESA-N 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
- C07D213/85—Nitriles in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Description
5 (BICYCLIC NITROGEN-HETEROARYL) PYRID-2-ONES AND THEIR USE FOR INCREASING CARDIAC CONTRACTILLITY
Field of the Invention
This invention relates to novel 5-bicyclic- heteroaryl-substituted-2-pyridones, useful as cardiotonic agents for the treatment of congestive heart failure, to their preparation and to pharmaceutical compositions comprised thereof.
Reported Developments
Congestive heart failure is a life-threatening condition in which myocardial contractility is depressed so that the heart is unable to adequately pump the blood returning to it. Normal pathologic sequelae include decreased cardiac output, venous pooling, increased venous pressure, edema, increased heart size, increased myocardial wall tension, and eventually cessation of contractility. Digitalis glyσosides have long been used to increase myocardial contractility and reverse the detrimental changes seen in congestive heart failure. More recently, dopamine, dobutamine, and amrinone have been used to provide necessary inotropic support for the failing heart.
Other reported inotropic drugs include the 5-pyridyl substituted pyridones, reported by Lesher and Opalka, where cardiotonic activity is exhibited when the substituents in the 3-position of the pyridones are hydrogen, cyano, amino, acetylamino, loweralkylamino, or diloweralkylamino (see U.S. Pat. Nos. 4,004,012, 4,072,746, 4,107,315, 4,137,233); when the 3-position of the pyridone is substituted by diloweralkyl amino methylene malonate (see U.S. Pat No. 4,199,586); and when the 3-position is acylamino (see U.S. Pat. No. 4,271,168). The most preferred 5-pyridyl-pyridone, "Amrinone", 3-amino-5-(4-pyridyl)-2(1H) -pyridone, is reported to cause a 39 to 98% increase in cardiac contractile force with a duration of action of more than three hours at doses of 1.9 to 10 mg/kg , as reported in U.S. Patent No. 4,107,315. At 10 mg/kg, however, an increase in heart rate is observed.
Lesher and Opalka have reported that 5-(4-pyridyl) -pyridones where the 3-position is halo substituted are useful intermediates for the preparation of compounds having cardiotonic properties.
Bormann has reported other 3-amino substituted pyridone cardiotonics having various monoσyσlic heterocyclic substituents in the 5-position (GB 2070606A; PCT published Appl. No. PCT/CH81/00023).
Pyridones wherein the 5-position is substituted by a bicyclic heteroaryl group have not been reported.
The present invention relates to a class of novel 5-bicyclic-heteroaryl-substituted-2-pyridones which exhibit cardiotonic activity in humans and mammals and which have the advantage of producing relatively small increases in heart rate at doses producing a positive inotropic effect.
Summary of the Invention
This invention relates to the novel compounds described by the structural Formula I:
wherein:
R1 is hydrogen, alkyl, hydroxyalkyl, or phenloweralkyl;
R3 is hydrogen, halo, alkyl, haloalkyl, cyano, amino, guanidino, thioureido, ureido, carboxyl, alkoxy, hydroxy, hydroxyalkyl, carbamoyl, acylamino, alkylamino, dialkylamino or nitro;
R4 and R6 are each independently hydrogen or alkyl;
R5 is a bicyclic heteroaryl group comprising a heteroaryl ring fused to an ortho-phenylene group, said heteroaryl ring including one or two nitrogen atoms in said ring;
and wherein: one or more of the heteroaryl group hydrogen atoms may be substituted by halo, alkyl, haloalkyl, hydroxyalkyl, hydroxy, alkylamino, dialkylamino, amino, alkoxy, aralkoxy, acylamino, cyano or nitro; and, the acid addition salts thereof.
This invention also relates to methods of preparing the compounds of Formula I, to pharmaceutical compositions for use in increasing cardiac contractility in humans and to the uses of these compunds in the treatment of cardiac failure in humans and other mammals.
Detailed Description
Certain of the compounds of Formula I may exist in enolic or tautomeric forms, and all of these forms are considered to be included within the scope of this invention.
The compounds of this invention which have particular usefulness as cardiotonic agents are described by the Formulae II to XI.
wherein:
R1, R3, R4 and R6 are as described above, and R and R' are each independently hydrogen, halo, alkyl, haloalkyl, hydroxyalkyl, hydroxy, dialkylamino, alkylamino, amino, acylamino, alkoxy, aralkoxy, cyano or nitro.
The preferred compounds are those defined by Formulae II to XI wherein the 6-position or the 7-position of the bicyclic heteroaryl group is R' substituted by the aforesaid substituents other than hydrogen.
The more preferred compounds are those defined by Formulae II to XI, wherein:
R1 is hydrogen, loweralkyl of C1-C3 carbon atoms or hydroxyloweralkyl of C2-C3 carbon atoms;
R3 is hydrogen, halo or haloloweralkyl of C2/-C3 carbon atoms;
R4 is hydrogen or loweralkyl of C1-C3 carbon atoms;
R6 is hydrogen or loweralkyl of C1-C3 carbon atoms;
R and R' are each independently hydrogen, loweralkyl, amino, mono- or di-lower alkylamino, hydroxy, lower alkoxy, benzyloxy, cyano, haloloweralkyl, halo or nitro.
Most preferred are those compounds disclosed by Formulae II to XI, wherein:
R1 is methyl, ethyl or hydroxyethyl;
R3 is hydrogen, fluoro, chloro, bromo or trifluoromethyl;
R4 is hydrogen;
R6 is hydrogen, methyl or ethyl; and
R and R' are hydrogen, methyl, ethyl, methoxy, benzyloxy, cyano, nitro, amino, alkylamino, or dialkylamino.
A special embodiment of the preferred compounds includes those compounds of Formula I, wherein:
R1 is methyl, ethyl or hydroxyethyl;
R3 is fluoro, chloro, bromo or trifluoromethyl;
R4 is hydrogen;
R5 is 4-guinolinyl, 2-quinolinyl, 1-isoquino linyl, or 3-isoquinolinyl; and
R6 is methyl or ethyl.
A second special embodiment of the preferred compounds includes those compounds of Formulae II-XI wherein the R' substituent in the six-position or the seven-position of the heteroaryl group is hydrogen, trifluoromethyl, nitro, halo, or cyano; provided that if both positions are substituted by R', then at least one of the R' substituents is other than hydrogen.
A third special embodiment of the preferred compounds includes those compounds of Formulae II-XI wherein R' in the six-position or the seven-position of the heteroaryl group is hydrogen, hydroxy, mono- or di-lower alkyl
amino, amino, benzyloxy, lower alkoxy, acetyl amino, hydroxy lower alkyl or lower alkyl; provided that if both positions are R' substituted, then at least one of the R' substituents is other than hydrogen.
Other embodiments include those compounds wherein:
R1, R3 and R4 are all hydrogen;
R , R4 and R6 are all hydrogen;
R3, R4 and R6 are all hydrogen;
R1 and R4 are both hydrogen;
R3 and R4 are both hydrogen;
R4 and R6 are both lower alkyl; and
R4 and R6 are both hydrogen.
As employed above and throughout the disclosure, the following terms, unless otherwise indicated, shall be understood to have the following meanings:
"Alkyl" means a saturated aliphatic hydrocarbon which may be either straight- or branched-chained containing from about one to about 5 carbon atoms.
"Lower alkyl" means an alkyl group as above, having 1 to about 3 carbon atoms.
The term "halo" includes all four halogens; namely, fluorine, chlorine, bromine and iodine.
"Haloalkyl" refers to a loweralkyl hydrocarbon group which may be substituted by one or more halo groups, such as trifluoromethyl, trifluorethyl, chloromethyl, etc.
"Phenloweralkyl" means a lower alkyl group in which one or more hydrogens is substituted by a phenyl group. Preferred groups are benzyl and phenethyl, etc.
"Acylamino" means an amino group substituted by an acyl radical of a lower alkanoic acid such as acetyl, propionyl, butyryl, valeryl or stearoyl.
"Hydroxy alkyl" means an alkyl group substituted by a hydroxy group. Preferred hydroxy loweralkyl groups include hydroxymethyl, 2-hydroxyethyl, 2-hydroxyproρyl, or 3-hydroxypropyl.
The compounds of this invention may be useful both in the free base form and in the form of salts, and both forms are within the scope of the invention. Acid addition salts can be formed and are simply a more convenient form for use; and in practice, use of the salt form inherently amounts to use of the base form. The acids which can be used to prepare the acid addition salts include preferably those which produce, when combined with the free base, pharmaceutically acceptable salts, that is, salts whose anions are non-toxic to the animal organism in pharmaceutical doses of the salts, so that the beneficial cardiotonic properties inherent in the free base are not vitiated by side effects ascribable to the anions. In practicing the invention it is convenient to form the free base form; however, appropriate pharmaceutically acceptable salts within the scope of the invention are those derived from mineral acids such as hydrochloric acid, sulfuric acid, phosphoric acid and sulfamic acid; and organic acids such as acetic acid, citric acid, lactic acid, tartaric acid, malonic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, cyclohexylsulfamic acid, quinic acid, and the like, giving the hydrochloride, sulfate, phosphate, sulfamate, acetate, citrate, lactate, tartarate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, cyclohexylsulfamate and quinate, respectively.
The acid addition salts of the compounds of this invention are prepared either by dissolving the free base in aqueous or aqueous-alcohol solution or other suitable solvents containing the appropriate acid and isolating the salt by evaporating the solution, or by reacting the free base and acid in an organic solvent, in which case the salt separates directly or can be obtained by concentration of the solution.
When a base is used for salt formation, it is preferred to form the same from a sodium or potassium base such as sodium hydroxide or potassium hydroxide.
Although pharmaceutically acceptable salts of said basic compound are preferred, all acid addition salts are useful as sources of the free base form even if the particular salt per se is desired only as an intermediate product as, for example, when the salt is formed only for purposes of purification and identification, or when it is used as an intermediate in preparing a pharmaceutically acceptable salt by ion exchange procedures.
The compounds of this invention may be prepared by one of the following synthetic routes.
The pyridone ring may be formed in essentially two steps by first reacting a bicyclic heteroarylmethyl compound with an appropriate activated methylidene reagent such as a Vilsmeier reagent and thereby result in the formation of the iminium salt of the α-bicyclicheteroaryl, β -enamino ketone or aldehyde. If desired, the iminium salt may be hydrolyzed to the β-enamino ketone or aldehyde for use in subsequent steps. An exemplary reaction is detailed in Scheme I.
Scheme I
The substitution pattern in the final product is predetermined in this reaction sequence by the choice of activated methylidene reagent which ensures symmetry in the R4 and R6 position of the final product. The activated methylidene reagent provides the carbon units which, in this reaction sequence, form the C-R4 and C-R6 groups of the pyridone ring. By choosing dimethylacetamide (R'=Me), for example, both R4 and R6 are methyl in the final product. Treatment of the α,β-enamino carbonyl compound or the iminum salt thereof with α-cyano acetamide in the presence of base results
in the 3-cyano pyridone X, which may be hydrolyzed to the 3-carbamoyl compound XI or the 3-carboxylic acid XII. (Scheme II)
Assymetry in the R4 and R6 positions of the final product may be introduced by using a bicyclic heteroarylketone as the starting material. The treatment of the α,β-enamino ketone with an appropriate nucleophile, such as α-cyanoacetaiαide in the presence of base, provides that R' will occupy the R4 position of the pyridone. (Scheme III)
The 3-halo compound may be prepared by way of the 3-amido or the 3-H compound, the former compound being prepared by hydrolyzing the cyano compound and the latter compound being prepared by deσarboxylation of the carboxylic acid (Scheme IV) .
The 3-trifluororaethyl compound XIV may be prepared by treating the 3-carboxy compound XIII with diethylamino sulfur trifluoride ( Scheme V) .
The following are illustrative examples of the preparation of the compounds of this invention and should not be construed as limitations thereof.
EXAMPLE I THE PREPARATION OF 3-CARBAMOYL-5- (4-QUINOLINYL)-2(1H) PYRIDONE
Step 1 N-[ 3-dimethylamino-2-(4-quinolinyl)-propenylidenel N-methylmethaneiminium chloride hydrochloride
A solution of 326 g of phosgene in 700 ml CH2Cl2 is cooled in an ice bath and added dropwise to DMF (767.6 g) while stirring at a temperature below 0ºC. A solution of 4-methylquinoline (100.2 g) in CH2Cl2 (100 ml) is added dropwise to the DMF-phosgene solution while maintaining the temperature below 0ºC. The reaction mixture is heated to reflux and about 350 ml of CH2Cl2 is distilled off while maintaining the reaction mixture temperature at about 60°C for a period of 2-1/2 hours. The reaction mixture is cooled, stirred overnight, filtered and the solid washed with DMF. The solid is taken up in a mixture of diethyl ether, CH2Cl2 and DMF, stirred and filtered. The solid is again taken up in ethyl acetate and acetonitrile, stirred, filtered and air dried to give the desired iminium hydrochloride as a yellow solid, M.P. 169-170°C dec.
Step 2 3-carbamoyl-5-(4-quinolinyl)-2(1H) pyridone
A 50% mineral oil dispersion of sodium hydride (12.0 g) is added to a solution of finely ground malonamide (11.2 g) in DMF (200 ml) and the mixture stirred at RT for 20 minutes. The methyl methaneiniminium chloride hydrochloride from the preceding step (32.6 g) is added as a solid to the reaction mixture. After the addition of the hydrochloride, the reaction mixture is heated and
stirred for 3 hours at a temperature of about 100 °C. The reaction mixture is cooled, filtered and the resulting solid washed with DMF and ether. The filtrate is concentrated under vacuum and the residual solid and the filtered solid are combined, dissolved in water and stirred overnight. The aqueous mixture is filtered through a pad of celite and the filtrate extracted with ether. The aqueous layer is made acidic by the dropwise addition of glacial acetic acid. The resulting precipitate is filtered, washed with H2O and air dried. The solid is crystallized from DMF to give after filtering and vacuum drying at 90°C overnight the desired pyridone as a tan solid, M.P. > 250°C.
EXAMPLE II THE PREPARATION OF 3-BROMO- 5-(4-QUINOLINYL)-2(1H) PYRIDONE
Step 1 3-Carboxy-5-(4-quinolinyl) -2( 1H) pyridone
38.1 g of 3-carbamyl-5-(4-quinolinyl)-2(1H) pyridone are suspended in 150 ml of H2O. 150 ml of concentrated sulfuric acid are added to the stirred suspension. The mixture is refluxed for 4 hours, cooled and stirred overnight. The reaction mixture is diluted with H2O to about 1.5 1, and while stirring the pH adjusted to about 5 by the addition of solid Na2CO3. The resulting solid is filtered, washed with H2O and air dried. The solid is taken up in boiling DMF, treated with charcoal and hot filtered. The filtrate is concentrated to about 1 1 and 800 ml of hot H2O added. The resulting precipitate is filtered from the cooled mixture and the solid washed with H2O and vacuum dried overnight to give the desired carboxylic acid as a yellow solid, M.P. > 250°C.
Step 2 5-(4-Quinolinyl)-2(1H) pyridone
A mixture of 3-carboxy-5-(4-quinolinyl)-2(1H) pyridone (39.4 g) and quinoline (250 ml) is refluxed under nitrogen for 24 hours, allowed to cool and stirred for a week. The reaction mixture is poured into about 1.5 1 of ether and the resulting precipitate filtered, washed well with ether and air dried. The solid is crystallized from isopropyl alcohol after treatment with charcoal to give after filtering and vacuum drying overnight the desired product as a tan solid, M.P. 217-218°C.
Step 3 3-Bromo-5-(4-quinolinyl)-2(1H) pyridone
A solution of bromine (9.5 g) in glacial acetic acid (20 ml) is added dropwise to a stirred solution of 5-(4-quinolinyl)-2(1H) pyridone (11.1 g) in glacial acetic acid (300' ml) at RT. The reaction mixture is stirred at 40-45°C for about 1 hour, poured into ice-H2O and the pH adjusted to about 6 by the addition of 50% aqueous sodium hydroxide. The mixture is allowed to stand overnight. Sodium bisulfite (about 5 g) is added to the mixture which is stirred a few minutes. The resultant solid is filtered and washed well with H2O. The solid is crystallized from isopropyl alcohol and after filtering and vacuum drying overnight gives the bromo pyridine compound as a pinkish purple solid, M.P. 227.5-229ºC.
EXAMPLE III THE PREPARATION OF 3-BROMO-1- METHYL-5-( 4-QUINOLINYL) -2-PYRIDONE
A 50% mineral oil suspension of NaH (1.7 g) is added to a solution of 3-bromo-5-( 4-quinolinyl)-2(1H) pyridone (7.0 g) in dry DMF (100 ml) and the mixture is stirred for 1 hour. Methyl iodide (4.9 g) is added to the stirred mixture via pipette. The reaction mixture is stirred for 1 hour, filtered and the filtrate concentrated under vacuum. The solid and the concentrated filtrate are suspended in H2O and ethyl acetate, filtered, washed with ethyl acetate and H2O, and air dried. The solids are combined and crystallized from DMF to give the desired methyl pyridone as a tan solid, M.P. > 250°C.
EXAMPLE IV THE PREPARATION OF 3-BROMO-1- ETHYL-5-( 4-QUINOLINYL) -2-PYRIDONE
A 50% mineral oil suspension of NaH (1.7 g) is added to a solution of 3-bromo-5-( 4-quinolinyl) -2( 1H) pyridone in dry DMF (100 ml) and the mixture stirred for 1 hour. Ethyl bromide (3.8 g) is added to the reaction mixture which is stirred at RT overnight. The reaction is concentrated under vacuum and the residue partitioned between H2O and ether. The insoluble solid is filtered and washed with ether and H2O. The solid is crystallized from ethyl acetate to give after filtering and vacuum drying the desired ethyl pyridone, M.P. > 250°C.
The following list of compounds may be prepared accordin to the above-described reaction sequences and using analogous reaction conditions and starting materials, which are either commercially available or prepared by methods known to those skilled in the art.
The compounds of Formula I possess positive inotropic activity and are useful as cardiotonic agents in the treatment of humans and other mammal for cardiac disorders including congestive heart failure. The effectiveness of the compounds of this invention as inotropic agents may be determined by the following pharmacologic tests which evaluate the change in cardiac contractile force upon exposure to a dose of said compounds. The anesthetized dog procedure is a standard test procedure; the inotropic results of this procedure generally correlate with the inotropic activity found in human patients.
Anesthetized Dog Procedure
Male mongrel dogs are anesthetized with pentobarbital (35 mg/kg i.v.) and intubated. Femoral artery and veins are cannulated for measurement of blood pressure and injection of compounds, respectively. A catheter connected to a Statham transducer is inserted into the left ventricle via the right carotid artery for measurement of left ventricular pressure, left ventricular end diastatic pressure and dP/dt. Lead II ECG and heart rate are also monitored. All parameters are measured on a Beckman Dynagraph.
The results of the anesthetized dog test show that the compounds of this invention exhibit positive inotropic activity and show dose related increases in contractile force with relatively small increases in heart rate.
A second test procedure which has been found to be an efficient means for ascertaining the inotropic activity of the compounds of this invention is described below.
Guinea Pig Atria Inotropic Screening at Low Calcium Concentrations
Guinea pigs are stunned by a sudden blow to the head; their chests are opened and hearts excised and placed in Kreb's medium (concentrations, mM: NaCl, 118.39; KCl, 4.70; MgSO4, 1.18; KH2PO4, 1.18; NaHCO3, 25.00; glucose, 11.66; and CaCl2, 1.25) gassed with a mixture of 95% O2 - 5% CO2. Left atria are removed and inserted into warmed (33°C) double jacketed tissue chambers containing oxygenated Kreb's medium (as above). The upper end of each tissue is attached to a Statham Universal Transducing Cell via a Statham Microscale Accessory. Resting tension on each tissue is set at 1 g and adjusted periodically.
Massive field stimulation is acheived via a pair of platinum or silver electrodes placed on opposite sides of the tissue. Electrodes are made from 20-gauge silver wire wound into a tight coil approximately 12-14 mm in diameter. Electrodes are connected to a Grass stimulator via a Grass constant current unit. Tissues are driven at 90 pulses per minute with a 5 msec duration at current levels 20% greater than threshold for continuous beat.
Cumulative concentrations of test drugs are added to the tissue bath at intervals sufficient to allow developed tension to peak at a new level.
The increase in developed tension in each tissue for each compound concentration is measured, and the results are averaged and used to construct cumulative concentration-response curves. Slopes for these regressions are calculated via the method of Finney (1971) and compared using Student's t-test.
The compounds of this invention can be normally administered orally or parenterally, in the treatment of cardiac disorders such as heart failure in humans or other mammals.
The compounds of this invention, preferably in the form of a salt, may be formulated for administration in any convenient way, and the invention includes within its scope pharmaceutical compositions containing at least one compound according to the invention adapted for use in human or veterinary medicine. Such compositions may be formulated in a conventional manner using one or more pharmaceutically acceptable carriers or excipients. Suitable carriers include diluents or fillers, sterile aqueous media and various non-toxic organic solvents. The compositions may be formulated in the form of tablets, capsules, lozenges, troches, hard candies, powders, aqueous suspensions, or solutions, injectable solutions, elixirs, syrups and the like and may contain one or more agents selected from the group including sweetening agents, flavoring agents, coloring agents and preserving agents, in order to provide a pharmaceutically acceptable preparation.
The particular carrier and the ratio of inotropic active compound to carrier are determined by the solubility and chemical properties of the compounds, the particular mode of administration and standard pharmaceutical practice. For example, excipients such as lactose, sodium citrate, calcium carbonate and dicalcium phosphate and various disintegrants such as starch, alginic acid and certain complex silicates, together with lubricating agents such as magnesium stearate, sodium lauryl sulphate and talc, can be used in producing tablets. For a capsule form, lactose and high molecular weight polyethylene glycols are among the preferred pharmaceutically acceptable carriers.
Where aqueous suspensions for oral use are formulated, the carrier can be emulsifying or suspending agents. Diluents such as ethanol, propylene glycol, glycerin and chloroform and their combinations can be employed as well as other materials.
For parenteral administration, solutions or suspensions of these compounds in sesame or peanut oil or aqueous propylene glycol solutions, as well as sterile aqueous solutions of the soluble pharmaceutically acceptable salts described herein can be employed. Solutions of the salts of these compounds are especially suited for intramuscular and subcutaneous injection purposes. The aqueous solutions, including those of the salts dissolved in pure distilled water, are also useful for intravenous injection purposes, provided that their pH is properly adjusted, suitably buffered, made isotonic with sufficient saline or glucose and sterilized by heating or by microfiltration.
The dosage regimen in carrying out the methods of this invention is that which insures maximum therapeutic response until improvement is obtained and thereafter the minimum effective level which gives relief. Thus, in general, the dosages are those that are therapeutically effective in increasing the contractile force of the heart or in the treatment of cardiac failure. In general, the oral dose may be between about 0.01 mg/kg and about 50 mg/kg (preferably in the range of 0.1 to 10 mg/kg), and the i.v. dose about 0.005 to about 30 mg/kg (preferably in the range of 0.01 to 3 mg/kg) , bearing in mind, of course, that in selecting the appropriate dosage in any specific case, consideration must be given to the patient's weight, general health, age, and other factors which may influence response to the drug. The drug may be administered orally 1 to 4 times per day, preferably twice daily.
Claims (17)
1. A compound according to the formula
wherein:
R1 is hydrogen, alkyl, hydroxyalkyl or phen loweralkyl;
R3 is hydrogen, halo, alkyl, haloalkyl, cyano, amino, guanidino, thioureido, ureido, carboxyl, alkoxy, hydroxy, hydroxyalkyl, carbamoyl, acylamino, alkylamino, dialkylamino or nitro;
R4 and R6 are each independently hydrogen or alkyl;
R5 is a bicyclic heteroaryl group comprising a heteroaryl ring fused to an ortho-phenylene group, said heteroaryl ring including one or two nitrogen atoms in said ring; and wherein: one or more of said heteroaryl group hydrogen atoms may be substituted by halo, alkyl, haloalkyl, hydroxyalkyl, hydroxy, alkylamino, dialkylamino, amino, alkoxy, aralkoxy, acylamino, cyano or nitro; or an acid addition salt thereof.
2. A compound according to Claim 1, wherein: R5 is 2-quinolinyl, 4-quinolinyl, 1-isoquinolinyl, 3-isoquinolinyl, 1-phthalazinyl, 2-quinoxalinyl, 2-quinazolinyl, 4-quinazolinyl, 3-σinnolinyl or
4-cinnolinyl; and wherein: one or more of the hydrogen atoms on the R5 substituent may be replaced by a halo, alkyl, haloalkyl, hydroxyalkyl, hydroxy, alkylamino, dialkylamino, amino, alkoxy, aralkoxy, acylamino, cyano or nitro group.
3. A compound according to Claim 2, wherein:
R5 is
and wherein R and R' are each independently hydrogen, halo, alkyl, haloalkyl, hydroxylalkyl, hydroxy, alkylamino, dialkylamino, amino, acylamino, alkoxy, aralkoxy, cyano, or nitro.
4. A compound according to Claim 2, wherein:
R1 is meth-yl, ethyl or 2-hydroxyethyl;
R3 is hydrogen, amino, acylamino, halo, cyano, haloalkyl, mono-or di-alkylamino, alkyl, guanidino, thioureido, ureido, carboxyl, alkoxy, hydroxy, nitro, or carbamoyl;
R4 and R6 are hydrogen, methyl or ethyl;
R5 is
R is hydrogen, hydroxy, lower alkoxy, benzyloxy, amino, alkylamino, lower alkyl, cyano, halo lower alkyl, halo, nitro, or dialkylamino.
5. A compound according to Claim 3 or 4, wherein:
R4 is hydrogen; and R6 is methyl or ethyl;
6. A compound according to Claim 3 or 4 , wherein R4 and R6 are methyl or ethyl.
7. A compound according to the formula
wherein:
R1 is lower alkyl;
R3 is halo or haloloweralkyl;
R4 and R6 are hydrogen or loweralkyl;
R5 is 2-quinolinyl, 4-quinolinyl, 1-isoquinolinyl, 3-isoquinolinyl, or 2-quinolinyl, 4-quinolinyl, 1-isoquinolinyl, or 3-isoquinolinyl substituted in the 6-position by lower alkyl, halo, halo loweralkyl, lower alkoxy, hydroxy, benzyloxy, cyano, nitro, amino, alkylamino, or dialkylamino; or an acid addition salt thereof.
8. A compound according to Claim 7 wherein R4 and Rg are lower alkyl.
9. A compound according to Claim 7 or 8, wherein R5 is 2-quinolinyl or 4-quinolinyl, or 2-guinolinyl or 4-quinolinyl substituted in the 6-position by lower alkyl.
10. 3-Carboxy-5-(4-quinolinyl)-2(1H)-pyridone or a non-toxic salt thereof.
11. 3-Bromo-5-(4-quinolinyl)-2(1H)-pyridone or a non-toxic salt thereof.
12. 5-(4-quinolinyl)-2(1H)-pyridone or a non-toxic salt thereof.
13. 3-Bromo-1-methyl-5-(4-quinolinyl)-2-pyridone or a non-toxic salt thereof.
14. 3-Bromo-1-ethyl-5-(4-quinolinyl)-2-pyridone or a non-toxic salt thereof.
15. 3-Carbamoyl-5-(4-quinolinyl)-2(1H)-pyridone or a non-toxic salt thereof.
16. A method for increasing cardiac contractility in a human or other mammal which comprises administering thereto an effective cardiotonic amount of a compound according to Claim 1.
17. A cardiotonic composition comprising an effective cardiotonic amount of a compound according to Claim 1 and a pharmaceutically acceptable carrier.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41064682A | 1982-08-23 | 1982-08-23 | |
US410646 | 1982-08-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2038683A true AU2038683A (en) | 1984-03-07 |
Family
ID=23625622
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU20386/83A Abandoned AU2038683A (en) | 1982-08-23 | 1983-08-23 | Bicyclic heteroaryl substituted pyridone compounds |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0118528A4 (en) |
JP (1) | JPS59501716A (en) |
AU (1) | AU2038683A (en) |
IT (1) | IT8367883A0 (en) |
WO (1) | WO1984000756A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5360808A (en) * | 1992-02-20 | 1994-11-01 | Hoechst Aktiengesellschaft | Arylcarbonylaminoalkyl-dihydro-oxo-pyridines, their production and their use |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2568251B1 (en) * | 1984-07-26 | 1988-05-27 | Mitsui Toatsu Chemicals | NEW ISOQUINOLEIN DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS |
JPS625963A (en) * | 1985-07-02 | 1987-01-12 | Mitsui Toatsu Chem Inc | Isoquinoline derivative |
US4785005A (en) * | 1986-06-25 | 1988-11-15 | Rorer Pharmaceutical Corporation | 6-(6-alkylpyridone)-carbostyril compounds and their cardiotonic uses |
US4859672A (en) * | 1986-10-29 | 1989-08-22 | Rorer Pharmaceutical Corporation | Pyrido[2,3-d]pyrimidinone and imidazo[4,5-b]pyrimidinone |
US5002944A (en) * | 1986-10-29 | 1991-03-26 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Compounds having cardiotonic activity |
ES2072015T3 (en) * | 1990-08-21 | 1995-07-01 | Upjohn Co | DERIVATIVES OF THE BISPHOSPHONIC ACID AS AN ANTI-ARTHRITIC AGENT. |
US5141931A (en) * | 1991-01-03 | 1992-08-25 | Sterling Winthrop Inc. | 5-Quinolinylpyridinones, cardiotonic compositions and methods |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2242787C2 (en) * | 1972-08-31 | 1982-01-21 | Bayer Ag, 5090 Leverkusen | 4-Phenyl-6-amino-3,4-dihydropyridon- (2) -3,5-dicarboxylic acid diethyl ester derivatives, a process for their preparation and pharmaceuticals containing them |
US3981882A (en) * | 1972-08-31 | 1976-09-21 | Bayer Aktiengesellschaft | Process for preparing 4-aryl of hetero-6-amino-3,4-dihydropyrid-2-one-3,5-dicarboxylic acid ester |
US4072746A (en) * | 1975-10-14 | 1978-02-07 | Sterling Drug Inc. | 3-Amino-5-(pyridinyl)-2(1H)-pyridinones |
US4271168A (en) * | 1979-12-26 | 1981-06-02 | Sterling Drug Inc. | Selected 3-acylamino-5-[4(or 3)-pyridinyl]-2(1H)-pyridinones |
DE3106460A1 (en) * | 1980-03-03 | 1982-01-28 | Sandoz-Patent-GmbH, 7850 Lörrach | 2 (1H) -PYRIDINONE DERIVATIVES, THEIR PRODUCTION AND THE PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME |
-
1983
- 1983-08-22 IT IT8367883A patent/IT8367883A0/en unknown
- 1983-08-23 JP JP58502958A patent/JPS59501716A/en active Pending
- 1983-08-23 EP EP19830902935 patent/EP0118528A4/en not_active Withdrawn
- 1983-08-23 AU AU20386/83A patent/AU2038683A/en not_active Abandoned
- 1983-08-23 WO PCT/US1983/001285 patent/WO1984000756A1/en not_active Application Discontinuation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5360808A (en) * | 1992-02-20 | 1994-11-01 | Hoechst Aktiengesellschaft | Arylcarbonylaminoalkyl-dihydro-oxo-pyridines, their production and their use |
Also Published As
Publication number | Publication date |
---|---|
EP0118528A4 (en) | 1985-09-09 |
IT8367883A0 (en) | 1983-08-22 |
WO1984000756A1 (en) | 1984-03-01 |
EP0118528A1 (en) | 1984-09-19 |
JPS59501716A (en) | 1984-10-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4432979A (en) | Pyridone compounds | |
US4721721A (en) | 6-(4-thiazole) compounds, cardiotonic compositions including the same, and their uses | |
KR100266305B1 (en) | Aryl group- or aromatic heterocyclic group-substituted aminoquinolone derivatives and anti-hiv agent | |
US4666923A (en) | Pyrrolobenzimidazoles for treating heart or circulatory diseases | |
US4666913A (en) | Hydroxy and aminothiazolyl-benzodiazinone compounds, cardiotonic compositions including the same, and their uses | |
SU1340589A3 (en) | Method of producing 2-(4-substituted piperazino)-4-amino-6,7-dimethoxy quinolines or hydrochlorides thereof | |
US4866074A (en) | Naphtheridinone- and pyridooxazinone-pyridone compounds, cardiotonic compositions including same, and their uses | |
US4166851A (en) | Certain imidazo(1,2a)pyridine derivatives | |
US4539321A (en) | 5-Diaza-aryl-3-substituted pyridone compounds | |
US4990509A (en) | Sulfonamide anti-arrhythmic agents | |
US5358953A (en) | Imidazopyridine PAF/H1 antagonists | |
US4408047A (en) | Imidazodiazines | |
US4465686A (en) | 5-(Hydroxy- and/or amino-phenyl)-6-(lower-alkyl)-2-(1H)-pyridinones, their cardiotonic use and preparation | |
AU2038683A (en) | Bicyclic heteroaryl substituted pyridone compounds | |
US4891372A (en) | Antiarrhythmic agents, compositions and method of use thereas | |
US4617393A (en) | 5-substituted-6-aminopyrimidines, composition and uses as cardiotonic agents for increasing cardiac contractility | |
US4826835A (en) | Pyridyl-pyridazinone and pyridyl-pyrazolinone compounds and their use in the treatment of congestive heart failure | |
US4599423A (en) | Preparation of 5-(hydroxy- and/or aminophenyl-6-lower-alkyl)-2(1H)-pyridinones | |
US4764512A (en) | Benzodiazinone-pyridone compounds, cardiotonic compositions including the same, and their uses | |
US5066654A (en) | 2-aryl-3-heterocyclicmethyl-3H-imidazo[4,5-b]pyridines as anxiolytics and anticonvulsants | |
US4593028A (en) | 5-hetero aryl-substituted-2-pyridones useful as cardiotonic agents for treatment of congestive heart failure | |
US4233301A (en) | Novel imidazoazines and imidazodiazines | |
US4783463A (en) | Pyridyl-pyridazinone and pyridyl-pyrazolinone compounds and their use in the treatment of congestive heart failure | |
CZ177892A3 (en) | AMINOMETHYL SUBSTITUTED 2,3-DIHYDROPYRAN(2,3-b)PYRIDINES, PROCESS OF THEIR PREPARATION AND THEIR USE IN MEDICAMENTS | |
US3378564A (en) | Certain pyridyl tetrazole derivatives |